Lv51
868 积分 2023-08-01 加入
Increasing stability of antibody via antibody engineering: Stability engineering on an anti-hVEGF
3小时前
待确认
Bevacizumab Antibody Affinity Maturation to Improve Ovarian Cancer Immunotherapy: In Silico Approach
3小时前
已完结
The functional capacity of the natural amino acids for molecular recognition
8天前
已完结
At the Heart of Immune Checkpoint Inhibitor–Induced Immune Toxicity
1个月前
已完结
Unveiling the molecular mechanism of Gi protein biased activation at mGlu2–mGlu4 heterodimers through Gaussian accelerated molecular dynamics simulations
1个月前
已完结
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
1个月前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
1个月前
已完结
Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation
1个月前
已完结
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
1个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
1个月前
已完结
皖公网安备34019202002308
